newsfilter
← Latest News
GlobeNewswire·

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on track for Q1 2026